Early Effect of 0.005% Estriol Vaginal Gel on Symptoms and Signs of Vulvovaginal Atrophy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: This study aims to assess the effect of ultralow dose 0.005% estriol vaginal gel in women with genitourinary syndrome of menopause (GSM).Methods: In this prospective and multicenter single-arm study, efficacy was assessed by the evaluation of the epithelial maturation value (MV), vaginal pH, symptoms and signs of vulvovaginal atrophy. Tolerability, acceptability, and the effect on intimate relationships were also evaluated.Results: We included 35 postmenopausal women with moderate-to-severe vaginal dryness. The most bothering symptom reported was vaginal dryness. The mean increase in the MV after 7 and 14 days of treatment were 22.1 (P < 0.001) and 39.9 (P < 0.001) points, with an increase in the superficial cells of 17.7 percentage points (pp) (95% confidence interval [CI], 7.9–27.4; P < 0.001) and 41.4 pp (95% CI, 28.2–54.6; P < 0.001) observed at the timepoints. Additionally, the pH decreased by 0.6 ± 0.7 (mean ± SD) at 7 days (P < 0.0001) and by 1.1 ± 0.8 at 14 days (P < 0.0001) from a baseline mean value of 6.3 ± 0.8. The severity of vaginal dryness (range, 0 [none] to 3 [severe]) was significantly reduced by a mean of 1.4 points (P < 0.0001) at 7 days and 2 points (P < 0.0001) at 14 days. Conclusions: Ultralow dose 0.005% estriol vaginal gel produced a rapid improvement of most relevant symptoms and signs of GSM. This clinically meaningful response was observed from the initial days of treatment, confirming a fast onset and a progressive action.
Abstract
Objectives: This study aims to assess the effect of ultralow dose 0.005% estriol vaginal gel in women with genitourinary syndrome of menopause (GSM).Methods: In this prospective and multicenter single-arm study, efficacy was assessed by the evaluation of the epithelial maturation value (MV), vaginal pH, symptoms and signs of vulvovaginal atrophy. Tolerability, acceptability, and the effect on intimate relationships were also evaluated.Results: We included 35 postmenopausal women with moderate-to-severe vaginal dryness. The most bothering symptom reported was vaginal dryness. The mean increase in the MV after 7 and 14 days of treatment were 22.1 (P < 0.001) and 39.9 (P < 0.001) points, with an increase in the superficial cells of 17.7 percentage points (pp) (95% confidence interval [CI], 7.9–27.4; P < 0.001) and 41.4 pp (95% CI, 28.2–54.6; P < 0.001) observed at the timepoints. Additionally, the pH decreased by 0.6 ± 0.7 (mean ± SD) at 7 days (P < 0.0001) and by 1.1 ± 0.8 at 14 days (P < 0.0001) from a baseline mean value of 6.3 ± 0.8. The severity of vaginal dryness (range, 0 [none] to 3 [severe]) was significantly reduced by a mean of 1.4 points (P < 0.0001) at 7 days and 2 points (P < 0.0001) at 14 days. Conclusions: Ultralow dose 0.005% estriol vaginal gel produced a rapid improvement of most relevant symptoms and signs of GSM. This clinically meaningful response was observed from the initial days of treatment, confirming a fast onset and a progressive action.
참고문헌 (23)
- Nappi RE, "The burden of vulvovaginal atrophy on women's daily living : implications on quality of life from a face-to-face real-life survey", Menopause, 26, pp.485~491 (2019)
- Moral E, "Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study", Climacteric, 21, pp.167~173 (2018)
- Kingsberg SA, "Vulvar and vaginal atrophy in postmenopausal women : findings from the REVIVE(REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs)survey", J Sex Med, 10, pp.1790~1799 (2013)
- Kingsberg SA, "The Women's EMPOWER survey : identifying women's perceptions on vulvar and vaginal atrophy and its treatment", J Sex Med, 14, pp.413~424 (2017)
- Cano A, "The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study", Menopause, 19, pp.1130~1139 (2012)
- Caruso S, "Effects of ultralow topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse", Menopause, 24, pp.900~907 (2017)
- Matarazzo MG, "Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?", Eur J Obstet Gynecol Reprod Biol, 222, pp.75~79 (2018)
- Hirschberg AL, "Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, doubleblind, placebo-controlled trial", Menopause, 27, pp.526~534 (2020)
- "Guidance for industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptomsrecommendations for clinical evaluation" (2003)[URL]
- Hustin J, "Cytologic evaluation of the effect of various estrogens given in postmenopause", Acta Cytol, 21, pp.225~228 (1977)
- Casper F, "Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group", Int Urogynecol J Pelvic Floor Dysfunct, 10, pp.171~176 (1999)
- North American Menopause Society, "Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society", Menopause, 17, pp.242~255 (2010)
- Sánchez-Rovira P, "A phase II prospective, randomized, double-blind, placebo-controlled and multicenter clinical trial to assess the safety of 0.005% estriol vaginal gel in hormone receptorpositive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitor in the adjuvant setting", Oncologist, 25, pp.e1846~e1854 (2020)
- Simon J, "Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet", Obstet Gynecol, 112, pp.1053~1060 (2008)
- Labrie F, "Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy", Menopause, 16, pp.907~922 (2009)
- Archer DF, "Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness : a phase 3, randomized, double-blind, placebo-controlled, multicenter trial", Menopause, 26, pp.611~621 (2019)
- Caruso S, "Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel", Menopause, 23, pp.47~54 (2016)
- Bachmann G, "Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis : a randomized controlled trial", Obstet Gynecol, 111, pp.67~76 (2008)
- Labrie F, "Efficacy of intravaginal dehydroepiandrosterone(DHEA)on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause", Menopause, 23, pp.243~256 (2016)
- Sturdee DW, "Recommendations for the management of postmenopausal vaginal atrophy", Climacteric, 13, pp.509~522 (2010)
- Kao A, "Dyspareunia in postmenopausal women : a critical review", Pain Res Manag, 13, pp.243~254 (2008)
- Constantine G, "vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia", Menopause, 26, pp.1259~1264 (2019)
- Panay N, "Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women", Maturitas, 124, pp.55~61 (2019)